Loading…
Bluejay Diagnostics, Inc. is projected to decline to $0.9296 by 2027, a -1% move from its current price of $0.9423. BJDX is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 8/4/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 6 | $0.8648 | $0.9417 | $1.03 | -0.06% |
| Aug 7 | $0.8342 | $0.9411 | $1.06 | -0.13% |
| Aug 8 | $0.8114 | $0.9405 | $1.09 | -0.19% |
| Aug 9 | $0.7926 | $0.9399 | $1.11 | -0.26% |
| Aug 10 | $0.7763 | $0.9393 | $1.14 | -0.32% |
| Aug 11 | $0.7618 | $0.9387 | $1.16 | -0.39% |
| Aug 12 | $0.7487 | $0.938 | $1.18 | -0.45% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $0.7487 | $0.938 | $1.18 | -0.45% |
| Week 2 | $0.6789 | $0.9338 | $1.28 | -0.90% |
| Week 3 | $0.6291 | $0.9296 | $1.37 | -1.35% |
| Week 4 | $0.5896 | $0.9254 | $1.45 | -1.79% |
| Week 5 | $0.5565 | $0.9212 | $1.53 | -2.24% |
| Week 6 | $0.5279 | $0.9171 | $1.59 | -2.68% |
| Week 7 | $0.5028 | $0.9129 | $1.66 | -3.12% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Bluejay Diagnostics, Inc. operates as a medical diagnostics company. It offers the Symphony technology platform which consists of an analyzer and single-use protein detection cartridges that are designed to provide measurements of key diagnostic biomarkers found in blood; and Symphony analyzer used to orchestrate sample processing of whole blood, plasma, serum, etc., biomarker isolation, and immunoassay preparation using non-contact centrifugal force.
The company also develops Symphony IL-6 tests for the monitoring of disease progression in critical care settings. In addition, it develops additional tests for Symphony, such as tests for myocardial infraction and congestive heart failure, as well as other tests using the Symphony platform. Bluejay Diagnostics, Inc.
was incorporated in 2015 and is headquartered in Acton, Massachusetts.
Bluejay Diagnostics, Inc. (BJDX) is categorized in Healthcare and currently trades with a price of $0.8786. The market cap is $909.1K and the company is ranked 5506 by market capitalization. The near-term price path shows a mixed outlook, with a path toward improvement in later years according to the multi-year forecast.
A major floor 8.7% below — a decisive break under it would weaken the trend.
The nearest floor, 8.7% below — buyers have tended to step in here.
The nearest ceiling, 373.3% above — a clean break opens room to run.
A major ceiling 500.7% above — clearing it would confirm fresh momentum.
Key BJDX support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of BJDX market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $0.9536 | Sell | $0.9448 | Sell |
| MA 10 | $1.05 | Sell | $1.05 | Sell |
| MA 20 | $1.19 | Sell | $1.34 | Sell |
| MA 50 | $2.46 | Sell | $1.92 | Sell |
| MA 100 | $2.17 | Sell | $2.40 | Sell |
| MA 200 | $3.40 | Sell | $23.41 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 31.75 | Neutral |
| Stoch RSI (14) | 7.59 | Buy |
| CCI (20) | -146.70 | Sell |
| Williams %R (14) | -100.00 | Info |
| MACD (12,26,9) | 0.03 | Buy |
| ROC (12) | -36.30 | Sell |
| Bollinger %B (20,2) | 0.04 | Neutral |
| Stochastic %K (14) | 0.00 | Buy |
| TRIX (15) | -3.24 | Sell |
| Awesome (5,34) | -1.07 | Sell |
| Ultimate (7,14,28) | 25.91 | Buy |
| Momentum (10) | -0.59 | Sell |
| Aroon Osc (25) | -100.00 | Sell |
| Hull MA (9) | 0.85 | Buy |
| ADX (14) | 32.54 | Sell |
| ATR (14) | 0.14 | Info |
The current market sentiment is NEUTRAL. The RSI(14) is 30, with a SMA50 of $2.49 and a SMA200 of $3.51. The stock sits on support at $0.879 and faces resistance at $4.54. The 30-day range trades between $0.4906 and $1.57. Annualized volatility is 200%, indicating substantial near-term price fluctuations.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $0.86 | $0.9423 | $1.21 | 0% | Neutral | |
| $0.6774 | $0.9296 | $1.38 | -1% | Neutral | |
| $0.5661 | $0.8262 | $1.31 | -12% | Neutral | |
| $0.5049 | $0.7765 | $1.29 | -18% | Bearish | |
| $0.4321 | $0.6968 | $1.21 | -26% | Bearish | |
| $0.5057 | $0.8525 | $1.53 | -10% | Neutral | |
| $0.6959 | $1.22 | $2.26 | +30% | Bullish | |
| $0.5939 | $1.09 | $2.07 | +15% | Neutral | |
| $0.483 | $0.9204 | $1.79 | -2% | Neutral | |
| $0.5064 | $1.00 | $2.00 | +6% | Neutral | |
| $0.634 | $1.41 | $3.09 | +50% | Bullish | |
| $1.17 | $2.60 | $5.98 | +176% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| August 2026 | $0.86 | $0.9423 | $1.22 | +0.00% |
| September 2026 | $0.7851 | $0.9543 | $1.21 | +1.27% |
| October 2026 | $0.7208 | $0.8884 | $1.15 | -6.90% |
| November 2026 | $0.7216 | $0.8996 | $1.18 | +1.27% |
| December 2026 | $0.7228 | $0.9106 | $1.21 | +1.22% |
Click any year to see its month-by-month BJDX forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
In 2026, BJDX is projected to trade between $0.86 and $1.21, averaging $0.9423 — a potential gain of 0% from today's $0.9423. A consolidation phase looks the most probable path here.
Bluejay Diagnostics, Inc.'s 2027 outlook centres on $0.9296, within a $0.6774 to $1.38 range. That is -1% versus the projected 2026 average. That marks a -1% change versus current levels. Price action looks broadly range-bound.
By 2028, BJDX could reach as high as $1.31, with a base case around $0.8262 and support toward $0.5661 — roughly -12% from $0.9423. A consolidation phase looks the most probable path here.
Expect BJDX to range from $0.5049 to $1.29 through 2029. The $0.7765 average target implies a -18% move from current prices. That is -6% versus the projected 2028 average. A cyclical pullback looks likely — prices rarely move in a straight line.
The BJDX price prediction for 2030 points to an average of $0.6968 (low $0.4321, high $1.21) — a potential decline of -26% on today's $0.9423. Expect choppier, lower action through this leg of the cycle.
In 2031, BJDX is projected to trade between $0.5057 and $1.53, averaging $0.8525 — a potential decline of -10% from today's $0.9423. That is up +22% on the projected 2030 average. Price action looks broadly range-bound.
Bluejay Diagnostics, Inc.'s 2032 outlook centres on $1.22, within a $0.6959 to $2.26 range. That is up +44% on the projected 2031 average. That marks a +30% change versus current levels. Buyers look set to stay in control over this stretch.
By 2033, BJDX could reach as high as $2.07, with a base case around $1.09 and support toward $0.5939 — roughly +15% from $0.9423. Price action looks broadly range-bound.
Expect BJDX to range from $0.483 to $1.79 through 2034. The $0.9204 average target implies a -2% move from current prices. That is -15% versus the projected 2033 average. A consolidation phase looks the most probable path here.
The BJDX price prediction for 2035 points to an average of $1.00 (low $0.5064, high $2.00) — a potential gain of +6% on today's $0.9423. Price action looks broadly range-bound.
In 2040, BJDX is projected to trade between $0.634 and $3.09, averaging $1.41 — a potential gain of +50% from today's $0.9423. That is up +40% on the projected 2035 average. Buyers look set to stay in control over this stretch.
Bluejay Diagnostics, Inc.'s 2050 outlook centres on $2.60, within a $1.17 to $5.98 range. That is up +85% on the projected 2040 average. That marks a +176% change versus current levels. Momentum favours further upside here.
Investing $1,000 in BJDX today (≈ 1,061.233153 BJDX) could be worth
$2,760.53
+$1,760.53 (+176%) by 2050 · US Dollar
Based on the average projected BJDX price of $2.6 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in BJDXwould be worth at today's price.
$1,000 invested in BJDX on Jul 31, 2025 (≈ 166.666667 BJDX) would be worth
$157.05
-$842.95 (-84.3%) today · 0.16× · US Dollar
Based on a BJDX entry price of $6 vs. today's $0.9423.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $1.03 | $914.85 | -8.5% |
| 1 month ago | $1.2 | $785.25 | -21.5% |
| 3 months ago | $1.92 | $490.78 | -50.9% |
| 6 months ago | $3.38 | $278.79 | -72.1% |
| 1 year ago | $6 | $157.05 | -84.3% |
| All time (4.7y) ago | $170,240 | $0.01 | -100.0% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our BJDX forecast.
Our base-case forecast reaches $1.90 around 2050.
Implied market cap at $1.90: $1.97M
Across the multi-year forecast, the asset shows a challenging near-term path before a notable turn in the longer term. For 2026 the min/avg/max are $0.8786 / $0.8786 / $1.13 with ROI 0 and sentiment NEUTRAL. In 2027 the range is $0.6285 / $0.8633 / $1.28 with ROI -1.7 and NEUTRAL sentiment.
2028 shows $0.5348 / $0.7811 / $1.24 with ROI -11.1 and NEUTRAL sentiment, followed by 2029 at $0.4632 / $0.7129 / $1.19 with ROI -18.9 and BEARISH sentiment. 2030 projects $0.4002 / $0.6459 / $1.12 with ROI -26.5 and BEARISH sentiment, while 2031 is $0.4817 / $0.8126 / $1.46 with ROI -7.5 and NEUTRAL sentiment. A turn to bullish appears in 2032 with $0.6454 / $1.14 / $2.10 and ROI 29.3.
The forecast stays bullish in 2040 at $0.5964 / $1.33 / $2.91 (ROI 50.9) and in 2050 at $1.08 / $2.40 / $5.53 (ROI 173.7). These are estimates, not guarantees, and reflect notable volatility as indicated by the figures.
Tap a question to reveal the answer.
2030 avg $0.6459; min $0.4002; max $1.12; ROI -26.5; sentiment BEARISH.
Yes. The max in 2027 is $1.28, in 2028 is $1.24, in 2029 is $1.19, in 2030 is $1.12, and the forecast shows a higher max in 2032 at $2.10.
The forecast shows NEUTRAL sentiment for 2026–2031 with some bears in 2029–2030, followed by a BEARISH-to-BULLISH shift beginning in 2032. Long-term years 2040 and 2050 show bullish outlooks with higher Avg values and positive ROIs.
Current price is $0.8786. The 30-day range is from $0.4906 to $1.57.
Annualized volatility is 200%, indicating high price variability over the forecasting horizon and contributing to the uncertainty of long-term projections.
Bluejay Diagnostics, Inc. Community Discussion
0Share your Bluejay Diagnostics, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.